WAT
57
3
SEE
45
3
NVDA
56
5
HPE
40
4
MAS
40
4
GILD
52
-2
JBHT
48
3
MO
51
3
JNPR
67
2
STT
45
-2
O
24
-11
DVA
56
2
INTC
36
3
AEP
48
-2
LOW
42
3
ACN
45
-2
AMT
32
4
SIG
41
-2
NTRS
50
6
FOX
75
5
WAT
57
3
SEE
45
3
NVDA
56
5
HPE
40
4
MAS
40
4
GILD
52
-2
JBHT
48
3
MO
51
3
JNPR
67
2
STT
45
-2
O
24
-11
DVA
56
2
INTC
36
3
AEP
48
-2
LOW
42
3
ACN
45
-2
AMT
32
4
SIG
41
-2
NTRS
50
6
FOX
75
5
Financhill
Back

Santen Pharmaceutical 10K Form

Sell
49

SNPHF
Santen Pharmaceutical

Last Price:
$10.53
Seasonality Move:
3.26%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive SNPHF News And Ratings

See the #1 stock for the next 7 days that we like better than SNPHF

SNPHF Financial Statistics

Sales & Book Value

Annual Sales: $2.1B
Cash Flow: $73M
Price / Cash Flow: 7.84
Annual Sales: $5.57
Price / Book: 1.82

Profitability

EPS (TTM): 0.50110
Net Income (TTM): $179.4M
Gross Margin: $1.2B
Return on Equity: 8.95%
Return on Assets: 6.16%

Santen Pharmaceutical Earnings Forecast

Key Santen Pharmaceutical Financial Ratios

  • The Gross Profit Margin over the past 20 years for SNPHF is 59.18%.
  • The Selling, General & Administrative Expenses for SNPHF have been equal to 30.31% of Gross Profit Margin.
  • The Research & Development expenses have been 8.42% of Revenue.
  • The Interest Expense is 10.00% of Operating Income.
  • The Net Earning history of SNPHF is 8.82% of Total Revenues.
  • Per Share Earnings over the last 20 years have been positive in 9 years.

Santen Pharmaceutical Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: OTCM
Industry: Pharmaceuticals
Sector: Health Care
Current Symbol: SNPHF
Website: santen.co.jp

Debt

Debt-to-Equity Ratio: 0
Current Ratio: 2.54
Quick Ratio: 2

Price-to-Earnings

Trailing P/E Ratio: 21
Forward P/E Ratio: 0

SNPHF Technical Analysis vs Fundamental Analysis

Sell
49
Santen Pharmaceutical (SNPHF) is a Sell

Is Santen Pharmaceutical a Buy or a Sell?